Slingshot members are tracking this corporate initiative:
Teva Completes Acquisition of Actavis Generics
Do you think this event is important to the companies below? How will it affect their stock price?
With the acquisition, Teva now has approximately 338 product registrations pending FDA approval and holds the leading position in first-to-file opportunities with approximately 115 pending ANDAs in the U.S. In Europe, after divestitures; Teva will have a pipeline capable of over 5000 launches across the region. In Teva growth markets including, Asia, Africa, Latin America, Middle East, Russia and CIS, there are now approximately 600 pending product approvals. Overall, Teva is planning for 1,500 generic launches globally in 2017.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Aug 02, 2016 Projected Implementation: Q3, 2016 Relevance Tracked Until: Q4, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords Acquisition, Generics